I have voted (mostly) republican for many, many elections.
I have voted (mostly) republican for many, many elections. I could not vote for Trump in 2016. Most registered GOPers said the same thing until that is all they had to vote for and then they showed the colors of a true politician and changed their "convictions" in a heartbeat. Some jumped on the bandwagon to ensure they had his base's support in upcoming elections. Some just outright quit instead of compromising their principles - and also couldn't be bothered fixing the mess that they helped create. Some, are walking the proverbial fence. Some just said phuck it and will do what they want and hope it doesn't hurt them.
I understand those who were "tired of the politicians & wanted something different" and supported and voted for Trump. They actually believed that he was a successful businessman. He was not. He is/was a con artist and didn't pay his bills and screwed over many, many small family owned business when he failed to pay his bills in AC.
I don't understand how anyone with a modicum of intelligence can still support him. Think about what he really is. If he was a Democrat and was exactly the same person & president, you would absolutely hate him and be looking to run him out of "the District". Look at the acts and not the actors. Just about everything he has done has been crap. That is exactly why so many world leaders laughed AT HIM when he was trying his "me; me; me" diatribe about all that he and his administration has done. Do not give him a pass because he happens to be a Republican.
1
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...
Continue Reading
Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...
Continue Reading
Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...
Continue Reading
Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...
Continue Reading
Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...
Continue Reading
Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....
Continue Reading
Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...
Continue Reading
Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...
Continue Reading
ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...
Continue Reading
Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...
Continue Reading
Top 5 Most Recently Viewed Articles
Celebrating Saia’s Commitment to Safety Saia Inc. (NASDAQ: SAIA) is thrilled to acknowledge the extraordinary efforts of nearly 8,000 employees, including dockworkers, mechanics, city drivers, and line drivers, who recently achieved a significant safety milestone. This recognition speaks volumes about the company's unwavering dedication to cultivating a safe work...
Continue Reading
Rhythm Pharmaceuticals Moves Forward with Significant Stock Offering Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is making headlines with its recent announcement regarding a sizable public offering aimed at strengthening its financial foundation. The Boston-based biopharmaceutical company, which specializes in treatments for rare neuroendocrine diseases, has priced an...
Continue Reading
FDA Grants Approval for Eli Lilly's Omvoh in Crohn's Disease Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical firm with remarkable market strength, has achieved a milestone with the FDA's endorsement of Omvoh (mirikizumab-mrkz) for treating adults dealing with moderately to severely active Crohn's disease. This approval follows the earlier sanction for...
Continue Reading
Understanding VINCI Group's Share Capital VINCI Group is a prominent French public limited company, known for its extensive involvement in construction and concessions globally. It's essential for investors to stay informed about the company's capital structure and voting rights as of a specific date. Current Capital Structure The share capital of VINCI Group is...
Continue Reading
Kaspi.kz Announces Upcoming Financial Results for 2024 Kaspi.kz (NASDAQ: KSPI) is gearing up to unveil its financial results reflecting the company's performance for the fourth quarter and the entire year of 2024. This eagerly anticipated announcement will take place on a Monday, a fitting choice for stakeholders looking for a fresh start to the week with new insights...
Continue Reading